Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year

Human gene therapy with rAAV2-vector was performed for the RPE65 form of childhood blindness called Leber congenital amaurosis. In three contemporaneous studies by independent groups, the procedure was deemed safe and there was evidence of visual gain in the short term. At 12 months after treatment,...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Cideciyan, Artur V., Hauswirth, William W., Aleman, Tomas S., Kaushal, Shalesh, Schwartz, Sharon B., Boye, Sanford L., Windsor, Elizabeth A.M., Conlon, Thomas J., Sumaroka, Alexander, Pang, Ji-jing, Roman, Alejandro J., Byrne, Barry J., Jacobson, Samuel G.
פורמט: Artigo
שפה:Inglês
יצא לאור: Mary Ann Liebert, Inc. 2009
נושאים:
Brief Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2829287/
https://ncbi.nlm.nih.gov/pubmed/19583479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2009.086
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים